9602 results about "Pharmaceutical drug" patented technology

The present disclosure relates to a medicament delivery device comprising a housing having a proximal end and contains a container of medicament positioned within the housing in a medicament container holder. The medicament container can be dual chambered, for example a pre-filled medicament container having a needle, a dose of medicament and one or more sliding stoppers. The medicament container holder can be configured with a recess or pocket to accommodate the loading of a dual chambered container and interact with an inside surface of the housing to rotationally fix the container holder relative to the housing and the medicament container. A tubular activation member, e.g., a needle cover, is slidably positioned within a housing of the delivery device to move from a first position to a second position, and then to a final locked position. A plunger rod can only move proximally relative to the needle cover when the needle cover is in the second position.

A device may include a data acquisition layer comprising a patient information collector and a drug information collector, each operable to ingest patient-specific clinical data and drug-specific data, respectively. A device may include an analysis engine comprising a multi-criteria ranking engine configured to compute composite suitability score for candidate medications by weighting one or more of medication efficacy, medication safety, medication resistance, medication cost, or patient-specific coverage factors. A device may include a presentation layer comprising a summary dashboard configured to display a ranked medication recommendation set produced by the analysis engine.

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

A vial adapter for connecting to an injection vial comprises an adapter body comprising a top wall and a sidewall, the sidewall projecting from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall. The receptacle is configured to receive at least a portion of a barrel head of an injection vial. A movable part comprises a base part and a tipped cannula fixed to the base part. The tipped cannula extends through the top wall into the receptacle, wherein the movable part is movable relative to the adapter body in a longitudinal direction. The tipped cannula comprises an elongated fluid channel, a tipped distal end configured to penetrate a pierceable stopper of the injection vial, and a channel aperture located inside the receptacle and located proximally offset from the tipped distal end.

This application provides a method for preparing compound I-b or a pharmaceutically acceptable salt thereof, wherein (S)-N-methylamino-1-(2-thiophene)-1-propanol reacts with 4-fluorobenzo[1,3]dioxolane in a system containing sodium hydride and potassium benzoate to obtain compound I-b. This method has short steps, mild reaction conditions, and is simple to operate, making it suitable for industrial scale-up; moreover, the obtained product has high purity and low isomer content.

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

The application discloses a kind of Zhang Xizheng pure Chinese medicine theory prescription medicine digital inheritance and intelligent analysis system.The system includes disease and syndrome differentiation rule engine subsystem, prescription three-way search subsystem, drug knowledge enhancement subsystem, medical record intelligent search subsystem, Zhang Xizheng school review subsystem and large language model interaction subsystem.The method performs the following steps: LLM clinical information extraction and disease prediction (extract symptoms, tongue, pulse, and 8 big disease classification prediction), disease and syndrome differentiation KB rule matching (8 big disease classification x multiple syndrome type weighted scoring matching), multi-source search (prescription three-way search+drug knowledge double-way vector recall and prescription-drug dynamic association+medical record multidimensional mixed scoring search), LLM fusion generation (inject all search results Zhang Xizheng school special prompt word generation theory prescription medicine analysis report) and Zhang Xizheng school four-dimensional review (western medicine perspective+air theory+drug use principles+theory prescription medicine consistency).The present application first realizes the computer formalization expression of Zhang Xizheng "disease differentiation before syndrome differentiation" mode and "air monism" theory, based on "Medical Western Medicine Record" 172 prescriptions+213 drugs / medical theory / medical conversation+137 cases to build a complete knowledge search and intelligent analysis system, with the ability of western medicine perspective+air theory+drug use principles+theory prescription medicine consistency.

1. Name of the product in this design: Medical Compressed Nebulizer (NBC-203). 2. Purpose of this design: To atomize liquid medications for easy oral inhalation. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key features: the front view.

The application discloses a kind of recombinant polypeptide and its application in preparation of the drug for treating autoimmune disease.The polypeptide includes the following amino acid sequence: X1X2EX3RHRFRQLDX4;Wherein, X1 is S or A, X2 is E or Q, X3 is M or I, X4 is S or T;The length of the polypeptide is 13-18 amino acids.The polypeptide provided by the application has stronger immunogenicity, is the important antigen peptide of chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS, type III prostatitis) and can be induced immune tolerance using the polypeptide, to provide effective treatment scheme for treating autoimmune disease (for example, type III prostatitis).The application also provides a kind of method for constructing mouse EAP model, using only one kind of adjuvant CFA, i.e.can successfully construct the model most matched with human chronic prostatitis / chronic pelvic pain syndrome.

A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided, which is useful as a pharmaceutical ingredient having S1P3 receptor antagonistic activity in the prevention and / or treatment an S1P3-mediated disease, wherein all symbols represent the same meaning as the symbols described in the specification. A drug is also provided, which containing, as an active ingredient, a compound having S1P3 receptor antagonistic activity in the prevention and / or treatment an S1P3-mediated disease.

The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

The utility model relates to medical instrument technical field, concretely is tracheal stent that can be absorbed and contains drug coating, including the casing of cylindrical cylinder shape, the casing includes longitudinal skeleton, ring skeleton, the drug groove of outward expansion and assembly groove, the drug coating strip is filled in the drug groove of outward expansion, the outside of casing is pasted with the film, the film includes the shrinkage film, contact touch and closed film, the utility model discloses through the degradation of closed film in patient trachea first, releases the stress on the corresponding casing at the drug groove of outward expansion, makes the drug groove of outward expansion, and the outer diameter of whole tracheal stent expands along with it, and drives drug coating strip synchronous expansion and presses outward and expands the patient place, realizes that the stent can be in the patient's body self -degradation, and the expansion force of stent can be slowly released in the process of degradation, thereby offset the stent wall thinning after degradation or the trachea natural growth leads to the stent expansion force reduction, dynamically maintained the expansion force of stent, increased the stability of stent.

The present disclosure provides immune cells comprising an exogenous T cell receptor (TCR) and T cell modulatory polypeptides (TMPs) for use in methods of treating a disease or condition. The TMPs comprise one or more immunomodulatory polypeptides that stimulate activation and / or proliferation of the immune cell. Also disclosed are methods of expanding a population of immune cells and methods of selectively delivering an immunomodulatory polypeptide using the same. Also disclosed are pharmaceutical combinations comprising the same and their use in methods of treating a disease or condition.

A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member, the plunger including a body portion having an inner wall defining an axial chamber and an outer wall cooperating with the inner wall to define a body thickness. The device may further include a plunger biasing member disposed at least partially within the axial chamber, the plunger biasing member configured to urge the plunger toward the distal end of the drug storage container.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

This application discloses a linker and its preparation method. The linker includes pharmacophore P, pharmacophore Q, and deoxynucleotides and / or deoxynucleotide derivatives connecting pharmacophore P and pharmacophore Q. Pharmacophore P is obtained by removing the protecting group from group B, and pharmacophore Q is obtained by removing the protecting group from group X. Group B is obtained by chemically modifying the benzylquinolone carboxylic acid pharmacophore, and group X is obtained by chemically modifying the zenomeprazole pharmacophore. The linker is prepared by linking group B and group X with deoxynucleotides and / or deoxynucleotide derivatives to form the linker, including solid-phase synthesis technology. The method of this application can automatically synthesize molecular probes or bivalent drugs containing two pharmacophores, thereby replacing the traditional stepwise linking method, enabling efficient construction of screening libraries, and allowing control of the spatial distance and spatial orientation of the pharmacophores by adjusting the number and base arrangement of deoxynucleotides.

In one example, a drug delivery system, such as an on-body or off-body delivery system, is configured to deliver a therapeutic drug to a patient. This system comprises a curved track, a plunger, and a driver. The driver translates the plunger along the curved track, causing the plunger's flexible plunger rod to bend along the curved track, driving the plunger seal of the drug container to dispense the liquid drug from the container.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

The present invention relates to a compound of formula (0-a) or a pharmaceutically acceptable salt thereof. The compounds of the invention bind to proton sensing G-protein coupled receptor type 4 (GPR4) and include a linker and a chelating agent that can comprise a radioligand. These compounds of the invention are particularly useful in imaging and in the treatment of solid tumors.

This application relates to a pharmaceutical composition of an aquaporin inhibitor and a method for producing the same. The pharmaceutical composition comprises 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of an aquaporin inhibitor and a method for producing the same have the following advantages: the process is simple, easy to operate, conducive to industrial production, good product stability, and a significantly reduced content of degradable impurities, which ensures pharmaceutical efficacy.

The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, a pharmaceutical composition thereof, and a use thereof in the treatment and / or prevention of diseases modulated by wild-type and / or mutant Bcr-Ab11 kinase.

Disclosed are methods and apparatus for delivering an active pharmaceutical ingredient (API) to a substrate, such as an edible. In particular, an API-containing liquid is dosed from a dosing head in small increments. Because the volume of API-containing liquid dosed in each increment is known, and the concentration of API in the API-containing liquid is known, the amount of API incrementally driven out of the dosing head in the API-containing liquid is known. Among the API driven out of the dosing head, a majority can be delivered to the substrate, for instance as individual successive droplets or as a stream. A minority can remain adhered to the dosing head as a residual API. A wash fluid can be applied to the dosing head to remove the residual API and deliver the residual API to the substrate.

The present disclosure relates to an apparatus that automates the transfer of liquid medicine between containers using a syringe, and is characterized by including a housing, a syringe automation unit, a liquid medicine container transfer automation unit, and a control unit.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

This invention relates to the application of frog seeds and their extracts in the preparation of sleep-improving products, belonging to the field of sleep health technology. Specifically, it relates to the application of frog seeds in the preparation of drugs, health products, or special diets with sleep-improving functions, and the application of frog seed extract in the preparation of drugs, health products, or special diets with sleep-improving functions. The frog seed extract is frog seed oil, obtained from frog seeds through supercritical CO2 extraction or cold pressing. The advantage is that animal pharmacodynamic experiments have confirmed that the frog seeds and their extracts of this invention can improve sleep. The sleep-improving functions specifically include one or more of the following aspects: shortening sleep onset time and alleviating sleep anxiety; improving sleep onset efficiency; prolonging sleep duration and increasing total sleep volume; reducing the number of nighttime awakenings and improving sleep continuity; improving the quality of deep sleep, increasing the proportion of deep sleep, and promoting bodily recovery.